CTMX

CytomX Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-16

Figures on this page computed 2026-11-08 12:56 UTC

Last close

2.35USD

Market data, 2026-11-04

CTMX: weekly closes from 3.62 on 2025-11-07 to 2.35 on 2026-11-04, a move of -35.1%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: -35.1%

Except where said otherwise: 10-K for 2025, filed 2026-03-16

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
-22.8%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
-99.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
0.04Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.17 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.18x

0.30x

1.49x

0.35x

0.30x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales1.18x
Its own average over 10 years, 64.7M.
Profit0.30x
Its own average over 10 years, -58.6M.
Free cash flow1.49x
Its own average over 10 years, -50.8M.
Debt0.35x
Its own average over 10 years, 12.0M.
Price0.30x
Its own average over 11 years, 8. Market data, 2026-11-04

Profit is furthest from its own average, at 0.30 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	476.1	n/a
2018-12-31	395.5	n/a
2019-12-31	178.8	100.0
2020-12-31	454.9	101.8
2021-12-31	248.0	141.5
2022-12-31	353.4	145.0
2023-12-31	672.8	162.8
2024-12-31	918.1	186.9
2025-12-31	506.6	304.3

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-107146
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-107146
Reported in: USD

The filing itself

Figures behind the shape

Growth

2.2%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate2.2%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-154.5%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-17.5%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on equity-17.5%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
Return on assets-11.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself

Margins

-29.4%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Operating margin-29.4%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Net margin-22.8%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Free cash flow margin-99.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself

Price

3.0x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
Price to book3.0x10-Q for 2025, filed 2026-08-06
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-337950
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-06
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
- 10-K for 2025, filed 2026-03-16
The filing itself
Price to sales ratio4.0x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself

Safety

0.04

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.04
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-06
The filing itself
Current ratio3.0910-Q for 2025, filed 2026-08-06
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-337950
Reported in
USD
- 10-Q for 2025, filed 2026-08-06
- 10-Q for 2025, filed 2026-08-06
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Altman Z-Score-2.34
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-107146
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- Computed from the 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.